Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO ...

(Image Credits: Pixabay ... Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

Experimental drugs make a notable contribution to how much and how quickly each of these Big Pharma players ... While Merck shares are significantly below the VWAP, there is also an unclosed ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346 ...

The deal is expected to close in the second quarter of 2025. Jiangsu Hengrui Pharma has given Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, except in ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

Keytruda, approved for several types of cancer, alone accounts for around 50% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue ...

Merck's stock trades at a low valuation as investors ... drug for up to $2 billion from Chinese healthcare company Hansoh Pharma. Given how massive the obesity drug market could be, topping ...

Recursion Pharma (RXRX) stock surges after the Food ... Intel (INTC) stock falls as tensions in the US-China trade war intensify. Five Below (FIVE) stock declines as China tariffs impact orders.

a TGF-beta-targeting PAH drug Merck acquired via its $11.5 billion takeover of Acceleron Pharma last year. Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck ...

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday ... companies in the two sectors Tuesday. For example, Merck signed a deal to license a potential blockbuster ...